Surmodics (NASDAQ:SRDX - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -0.670--0.470 for the period, compared to the consensus estimate of -0.940. The company issued revenue guidance of $118.0 million-$120.0 million, compared to the consensus revenue estimate of $119.7 million.
Surmodics Stock Performance
Shares of SRDX stock traded up $7.64 during trading hours on Wednesday, hitting $33.33. 256,562 shares of the company were exchanged, compared to its average volume of 59,929. The firm has a fifty day simple moving average of $28.54 and a 200 day simple moving average of $31.62. The stock has a market capitalization of $474.49 million, a price-to-earnings ratio of 88.53 and a beta of 1.01. Surmodics has a 52-week low of $16.79 and a 52-week high of $39.41. The company has a current ratio of 4.84, a quick ratio of 3.97 and a debt-to-equity ratio of 0.24.
Analyst Ratings Changes
Several research analysts recently commented on SRDX shares. Needham & Company LLC cut their price objective on shares of Surmodics from $47.00 to $43.00 and set a buy rating for the company in a report on Wednesday. StockNews.com downgraded shares of Surmodics from a strong-buy rating to a buy rating in a report on Wednesday, April 24th.
Get Our Latest Analysis on Surmodics
Surmodics Company Profile
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Further Reading
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
